Please enable Javascript
Renal Cell Carcinoma Roundtables
Refractory RCC: Third-Line Treatment Considerations
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel concludes with the applications, challenges, and future prospects of belzutifan in treating advanced kidney cancer.
Improving Outcomes in Patients With Chromophobe, Papillary RCC
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel explores the latest research in rare subtypes of kidney cancer, emphasizing the need for biology-driven trials.
Personalized RCC Care: Decreasing Overtreatment, Identifying Cured Patients in the Adjuvant Setting
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel emphasizes the need to decrease RCC overtreatment and to identify cured patients in the adjuvant setting.
Considerations for Managing Patients on Maintenance RCC Therapy
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel offers evolving strategies for managing treatment durations and holds for patients on IO/TKI and PD-1 regimens.
CheckMate 67T: Do Recent Updates Make This Practice-Changing?
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel highlights the potential practice-changing impact of subcutaneous PD-1 agents for kidney cancer treatment.Dr.
RCC Treatment Sequencing and Combination Approaches: JAVELIN Renal 101 and COSMIC-313
Katy Beckermann, MD, PhD
Renal Cell Carcinoma
|
July 23, 2024
The panel focuses on the final OS analysis from the JAVELIN Renal 101 trial and the challenges of combining IOs with TKIs.
Expert Panel Shares Forward-Looking Thoughts on RCC Treatment, Clinical Trials
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel shared their excitement for the road ahead in kidney cancer.
RCC Panel Discusses Treatment Response, Dosing, Patient Management, and More
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel addressed different dosing scenarios and shared tips on how to counsel patients on their treatment.
LITESPARK-005 Study Results and Thoughts on Second-Line RCC Treatment
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel shared their thoughts on quality of life data presented from the LITESPARK-005 trial of belzutifan.
CheckMate 67T Offers a Look at a Different Treatment Route of Administration
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel discussed the impact of a subcutaneous formulation of nivolumab.
Panel Discusses Other RCC Treatment Options: Radiation Techniques, Surgery, and More
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel discussed the role of SBRT and some exciting studies like SAMURAI.
CheckMate 9ER: Frontline Nivolumab/Cabozantinib in RCC Patients With Metastases, QOL Considerations
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel discussed CheckMate 9ER, which assessed quality of life outcomes in patients receiving cabozantinib/nivolumab.
RCC Panel Reacts to Long-Term Follow-Up From CheckMate 214
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel shared their thoughts on the 8-year follow-up data from CheckMate 214.
ASCO GU Data Updates: KEYNOTE-564 and CheckMate 914
Brad McGregor, MD
Renal Cell Carcinoma
|
June 3, 2024
The panel discussed two studies that assessed adjuvant treatment: KEYNOTE-564 and CheckMate 914.
Looking Ahead in RCC: Belzutifan, Triplets, Treatment Combinations, and More
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel forecasted some of the major questions that will be answered regarding belzutifan, triplet combinations, and more.
CheckMate 67T and the Potential of Subcutaneous Nivolumab Administration
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel transitioned to relevant considerations from the CheckMate 67T study and thoughts on subcutaneous nivolumab.
CheckMate 9ER: What Is the Impact for RCC?
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel highlighted the CheckMate 9ER study and implications for clinical practice.
Panel Shares Thoughts on RCC Data: CheckMate 914, 214 and IMDC Selection Criteria
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel swapped opinions on data pertaining to CheckMate 914, CheckMate 214, and IMDC selection criteria.
Panel Discussion on OS Data From KEYNOTE-564 Study and Post-Relapse Treatment Selection
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel discussed the groundbreaking OS results from the KEYNOTE-564 study and implications for their practice.
The Role of SBRT and Metastasis-Directed Therapy for RCC Treatment, Variant Histology Considerations
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel considered the role of SBRT as well as MDT in RCC. They also weighed in on variant histology considerations.
Frontline RCC Treatment Selection: IO/IO Versus IO/TKI
Rana McKay, MD
Renal Cell Carcinoma
|
May 31, 2024
The panel weigh the treatment considerations of IO/IO versus IO/TKI for advanced renal cell carcinoma.
What’s on the Horizon for RCC Treatment and Care?
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel shares their outlook on the near future for renal cell carcinoma research, treatment, and care.
RCC Highlights From ASCO GU: Adjuvant Treatment, Immunotherapy, Toxicities, and More
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel discussed important takeaways from RCC studies presented at ASCO GU.
KEYNOTE-B61 Study Results and a Focus on Non-Clear Cell Kidney Cancer
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
The panel shifts to focus on the current state of non-clear cell kidney cancer.
Longer-Term Follow-Up on Frontline IO and TKI Studies and Impacts to Treatment Selection
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. Voss compares IO/IO and TKI/IO treatment options, as well as toxicity considerations.
The Latest Data on IO/TKI Versus IO/IO in Frontline RCC
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. McDermott advocates for immune therapy in frontline RCC care.
ASCO GU Data Updates in Frontline Kidney Cancer: Was Anything Practice Changing?
Brian Rini, MD, FASCO
Roundtable
|
February 7, 2024
Dr. Plimack shared her approach to frontline clear cell kidney cancer treatment selection.
Adjuvant RCC Treatment Considerations and Final Thoughts on RCC Therapy
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel provides their concluding thoughts on the frontline and refractory RCC treatment landscape.
Panel Reacts to CONTACT-03 Data Presented at ASCO 2023, Thoughts on Adjuvant Therapy
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel discusses treatment options in the refractory RCC setting.
Panelists Share What Is Most Exciting in Frontline Kidney Cancer
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel discusses what is most exciting to them in the frontline RCC field.
Patient Selection for IO/IO Versus IO/TKI in the Frontline Setting
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel discusses toxicity management and use of precision medicine.
Panelists Share How CLEAR and KEYNOTE-426 Data Presented at ASCO 2023 Impact Treatment Decisions
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panelists debate the use of IO/IO versus IO/TKI regimens for frontline RCC therapy.
ASCO 2023 Data in Frontline RCC: CLEAR and KEYNOTE-426 Trial Updates
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
Dr. Rini describes the CLEAR and KEYNOTE-426 studies presented at ASCO 2023.
Panelists Discuss Their Algorithm for Treating Frontline RCC
Brian Rini, MD, FASCO
Roundtable
|
July 5, 2023
The panel discusses the approach to frontline treatment selection for patients with RCC.
Panelists Weigh In on Interesting Data Still to Come in RCC
Brian Rini, MD, FASCO
Roundtable
|
August 22, 2023
The panel shares interesting clinical trial data in development, including CONTACT-03, TiNivo-2, and more.
What Does the Future Hold for Triplet Combinations in RCC?
Brian Rini, MD, FASCO
Roundtable
|
March 15, 2023
The panel discusses triplet combinations in development for RCC.
COSMIC-313 Trial Results and Implications for Triplet RCC Therapy
Brian Rini, MD, FASCO
Roundtable
|
March 15, 2023
The panel discusses the disappointing results of the COSMIC-313 trial.
What Is the Most Exciting Ongoing Clinical Trial in RCC?
Monty Pal, MD
Roundtable
|
March 15, 2023
The panel discusses exciting ongoing clinical trials, including 304, TiNivo-2, PDIGREE, and more.
Review of the Data of Frontline Treatment for Non-Clear Cell Kidney Cancer
Monty Pal, MD
Roundtable
|
August 23, 2023
The panel shares how they treat frontline papillary kidney cancer.
RCC Doublet Considerations: Immune-Mediated Toxicity, Duration of Treatment, and More
Brian Rini, MD, FASCO
Roundtable
|
March 15, 2023
The panel discusses treatment-related toxicities and when to consider stopping treatment.
Patient Scenarios and Treatment Considerations in the Adjuvant RCC Setting
Monty Pal, MD
Roundtable
|
March 15, 2023
The panel considers how to treat in the adjuvant setting following prior IO/IO or IO/TKI treatment.
Choosing an IO/TKI Doublet for RCC Patients: Efficacy Data, Dosing, and More
Brian Rini, MD, FASCO
Renal Cell Carcinoma
|
February 5, 2024
The panel compares three treatment regimens.
Rechallenging Treatment in Third-line and Subsequent RCC Settings
Monty Pal, MD
Roundtable
|
June 20, 2023
The panel debates the "phenomenon" of rechallenging treatment in subsequent treatment lines.
CheckMate 8Y8 Trial in Progress: What Are the Implications for This Doublet?
Brian Rini, MD, FASCO
Roundtable
|
April 26, 2023
The panel discusses the CheckMate 8Y8 clinical trial.
Second-line Treatment Options for RCC
Monty Pal, MD
Roundtable
|
April 26, 2023
The panel discusses the challenge of second-line RCC treatment options and how to sequence therapy.
CheckMate-9ER Discussion: Depth of Response With First-line Cabozantinib/Nivolumab
Monty Pal, MD
Roundtable
|
April 10, 2023
The panel discusses outcomes from the CheckMate-9ER trial and addresses the importance depth of response.
TKI/IO Comparison: Lenvatinib/Pembrolizumab Versus Cabozantinib/Nivolumab Versus Axitinib/Pembrolizumab
Monty Pal, MD
Roundtable
|
March 31, 2023
The panel compares three TKI/IO treatment combinations.
In RCC, What Is the Optimal Treatment for Intermediate/Poor-Risk Disease?
Monty Pal, MD
Roundtable
|
March 14, 2023
The panel discusses considerations for treatment choice in patients with poor- and intermediate-risk disease.
Who Is the Appropriate RCC Patient to Receive Combination Therapy?
Brian Rini, MD, FASCO
Roundtable
|
March 14, 2023
The panel discusses which patients in their practices would be candidates for ipilimumab/nivolumab combination.
Which Patients With RCC Are Right for Monotherapy?
Brian Rini, MD, FASCO
Roundtable
|
March 14, 2023
The panel discusses monotherapy treatment for RCC.
Advertisement
Advertisement
Advertisement
Advertisement